Processing your payment...
Please do not close your browser.

Drugs for Malaria Market- Global Growth, Trends and Forecast (2022-2029) By Type (Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds) By Applications (Prevention, Treatment, Others) and By Regions

12 Jul, 2022 | 130 Pages
Shares
facebook sharing button
linkedin sharing button
twitter sharing button
sharethis sharing button

Over the forecast period, the Drugs for Malaria Market will register a CAGR of 4.5 % in terms of revenue and the global market size will reach USD xx Billion by 2029.

Drugs for Malaria Market Overview

Malaria is an infectious disease that enters the body of a person by the bite of an infected female Anopheles mosquito, passing parasites. In addition, these parasites settle inside liver cells, where they develop and reproduce. Once within red blood cells, they advance to a stage known as merozoites. The red cells are destroyed as the merozoites multiply inside of them, leading to additional symptoms including fever, exhaustion, nausea, and headaches. Additionally, Drugs for Malaria are those that are used to both treat and prevent malaria. For the treatment of malarial infection, a variety of medications, including quinine, chloroquine, proguanil, mefloquine, pyrimethamine, and others, are sold on the market.

The rise in malaria incidence in developing nations is a key factor driving the demand for Drugs for Malaria. In addition, the market is growing as a result of increased government awareness campaigns and a spike in research into novel Drugs for Malaria. However, one of the main factors limiting the growth of the market for Drugs for Malaria is the lack of healthcare knowledge in developing nations. On the other hand, throughout the forecast period, developing economies' economic prospects are anticipated to provide profitable chances for market expansion.

What are our Drugs for Malaria Market report scope?

 

Report Attributes

 

 

Report Details

 

Forecast Period 2022 to 2029

 

CAGR of 4.5 % during the review period (2022 to 2029).

 

By Type

  • Aryl Aminoalcohol Compounds
  • Antifolate Compounds
  • Artemisinin Compounds

 

By Applications

 

 

 

 

  • Prevention
  • Treatment
  • Others

 

 

 

By Companies

  • Cipla
  • Guilin Pharmaceutical
  • IPCA Laboratories
  • GlaxoSmithKline
  • Mylan Labs
  • Roche
  • Novartis
  • Sanofi Aventis
  • Ajanta Pharma

 

 

 

 

Regions Covered

 

  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

 

 

 

 

 

 

 

 

Countries Covered

  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • Middle East & Africa
  • Latin America

Base Year

2022

 

Historical Year

 

 

2017 to 2021

Forecast Year

 

2022 to 2029

Number of Pages

130

 

Customization Available

 

 

Yes, the report can be customized as per your needs

Frequently Asked Questions

What are the current market size and compound annual growth rate (CAGR) of the Drugs for Malaria Market during the forecast period (2022-2029)?

The Drugs for Malaria Market is growing at a CAGR of 4.5 % over the next 7 years.

Who are the key players in the Drugs for Malaria Market?

Cipla, Guilin Pharmaceutical, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aventis, Ajanta Pharma, and Others.

What region does this Drugs for Malaria Market report cover?

North America (the United States, Canada, and Mexico), Europe (Germany, France, UK, Russia, and Italy), Asia-Pacific (China, Japan, Korea, India, and Southeast Asia), South America (Brazil, Argentina, Colombia, etc.), The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

What are the significant Type of Drugs for the Malaria Market?

Aryl Aminoalcohol Compounds, Antifolate Compounds, Artemisinin Compounds.

What are the significant Applications of Drugs for the Malaria Market?

Prevention, Treatment, Others.

Who are the Major Players in the Drugs for Malaria Market?

Market Growth Reports lists out all the Drugs for Malaria Market companies that are presently striving to reduce the impact of the Covid-19 pandemic on the Market- Cipla, Guilin Pharmaceutical, IPCA Laboratories, GlaxoSmithKline, Mylan Labs, Roche, Novartis, Sanofi Aventis, Ajanta Pharma, Others

Industry News:

Cipla releases a quality-guaranteed Pediatric severe malaria treatment with rectal artesunate suppositories

The introduction of 100 mg Artesunate Rectocaps/Rectal Artesunate Suppositories (RAS), life-saving pre-referral intervention for the management of severe malaria in young children, is announced by MMV and Cipla Ltd, a multinational pharmaceutical business.

RAS 100 mg manufactured by Cipla, which was initially created by TDR, the WHO-hosted Special Programme for Research and Training in Tropical Diseases, has recently been added to the Global Fund Expert Review Panel's list of quality-assured medicines as the WHO prequalification process for this medication enters its final stages. With this approval, it becomes the first RAS product with quality assurance.

What are the major Types and Applications of Drugs for the Malaria Market?

By Type, it is segmented into

  • Aryl Amino Alcohol Compounds
  • Antifolate Compounds
  • Artemisinin Compounds

By Applications, it is segmented into

  • Prevention
  • Treatment
  • Others

Drugs for Malaria Market Regional Analysis

Due to the rapidly increasing frequency of malaria in the area, the Middle East and Africa have held the lion's share of the market share and are predicted to do so going forward. The Globe Health Organization (WHO) estimates that there were 228 million cases of malaria in the world in 2018, with the WHO African Region bearing an abnormally large amount of the burden. The Middle East and Africa are predicted to have one of the greatest market shares for Drugs for Malaria as a result.

Due to increased knowledge of the use of Drugs for Malaria for early detection of the illness and improved treatment, Asia-Pacific is also anticipated to see the fastest rise.

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Middle East & Africa
    • Latin America
  1. INTRODUCTION
    1. MARKET DEFINITION
    2. MARKET DYNAMICS
    3. MARKET SEGMENTATION
    4. REPORT TIMELINES
    5. KEY STAKEHOLDERS
  2. RESEARCH METHODOLOGY
    1. DATA MINING
      1. SECONDARY RESEARCH
      2. PRIMARY RESEARCH
      3. SUBJECT MATTER EXPERT ADVICE
    2. QUALITY CHECK
    3. FINAL REVIEW
      1. DATA TRIANGULATION
      2. BOTTOM-UP APPROACH
      3. TOP-DOWN APPROACH
      4. RESEARCH FLOW
  3. EXECUTIVE SUMMARY
    1. INTRODUCTION
    2. GLOBAL DRUGS FOR MALARIA BY TYPES
    3. GLOBAL DRUGS FOR MALARIA BY APPLICATIONS
  4. MARKET DYNAMICS
    1. DRIVERS
      1. INCREASING DEMAND FOR MSM SUPPLEMENT
    2. RESTRAINTS
      1. STRINGENT ENVIRONMENTAL REGULATIONS
      2. HIGH COST OF MATERIALS
    3. OPPORTUNITIES
      1. DRUGS FOR MALARIA GROWTH
    4. APPLICATION OF DRUGS FOR MALARIA IMPACT OF COVID 19
  5. GLOBAL DRUGS FOR MALARIA, BY TYPES
    1. INTRODUCTION
    2. ARYL AMINO ALCOHOL COMPOUNDS
    3. ANTIFOLATE COMPOUNDS
    4. ARTEMISININ COMPOUNDS
  6. GLOBAL DRUGS FOR MALARIA, BY APPLICATIONS
    1. INTRODUCTION
    2. PREVENTION
    3. TREATMENT
    4. OTHERS
  7. GLOBAL DRUGS FOR MALARIA, BY REGION
    1. NORTH AMERICA
      1. US
      2. CANADA
      3. MEXICO
    2. EUROPE
      1. GERMANY
      2. FRANCE
      3. UK
      4. ITALY
      5. RUSSIA
      6. REST OF EUROPE
    3. APAC
      1. CHINA
      2. SOUTH KOREA
      3. JAPAN
      4. INDIA
      5. AUSTRALIA
      6. ASEAN
      7. REST OF APAC
    4. MIDDLE EAST AND AFRICA
      1. SAUDI ARABIA
      2. UAE
      3. SOUTH AFRICA
      4. TURKEY
      5. REST OF MEA
    5. SOUTH AMERICA
      1. BRAZIL
      2. REST OF MEA
      3. ARGENTINA
      4. REST OF SOUTH AMERICA
  8. COMPETITIVE LANDSCAPE
    1. MERGERS, ACQUISITIONS, JOINT VENTURES, COLLABORATIONS,
    2. AND AGREEMENTS
      1. KEY DEVELOPMENT
    3. MARKET SHARE PERCENT/RANKING ANALYSIS
    4. STRATEGIES ADOPTED BY LEADING PLAYERS
  9. COMPANY PROFILES
    1. BUSINESS OVERVIEW
    2. COMPANY SNAPSHOT
    3. PRODUCT BENCHMARKING
    4. STRATEGIC INITIATIVES
      1. CIPLA
      2. GUILIN PHARMACEUTICAL
      3. IPCA LABORATORIES
      4. GLAXOSMITHKLINE
      5. MYLAN LABS
      6. ROCHE
      7. NOVARTIS
      8. SANOFI AVENTIS
      9. AJANTA PHARMA

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Request A Sample

Please Choose License Type

  • Single User License
    $2500
  • Site License
    $3000
  • Global License
    $5000

How can we help you?

Reach us with your research requirements and we shall provide the optimum solution to suit your needs.

Curioust about Multiple Reports?

Discounts available for multiple report purchases.

Contact Us

Our Clients

  • Korean Institute of Tuberculosis
  • Sanyo chemical Industries LTD
  • Novartis
  • Hisamitsu
  • Pfizer
  • AbbVie
  • RevHealth
  • Zeon Corporation
  • Abbott (Established Pharmaceutical Products)
  • Sinopharm (pharmaceutical distribution segment)
  • Takeda Pharmaceutical
  • Gilead Sciences
  • Sartorius
  • Zavation
  • Permobil
  • Ansell
  • Cefla